Tardive Dyskinesia Therapeutics Global Market Report 2026

Tardive dyskinesia therapeutics encompass treatments developed to manage or reduce the involuntary, repetitive movements associated with this neurological condition. These therapies are designed to address underlying neurological imbalances, which are often linked to the long-term use of certain medications. The primary objective is to enhance patient quality of life by decreasing the severity and frequency of motor symptoms, improving functional capabilities, and limiting long-term complications.

The main drugs used in tardive dyskinesia therapeutics include deutetrabenazine, valbenazine, and others. Deutetrabenazine is a vesicular monoamine transporter type 2 (VMAT2) inhibitor prescribed to treat involuntary movements related to tardive dyskinesia. It is available in various product forms, including solid dosage forms such as tablets and capsules, as well as liquid formulations and injections. Deutetrabenazine is used for indications including antipsychotic-induced tardive dyskinesia, other drug-induced tardive dyskinesia, and idiopathic tardive dyskinesia. These therapies are utilized by end users such as hospitals, clinics, specialty treatment centers, and homecare settings.

Tariffs have influenced the tardive dyskinesia therapeutics market by increasing costs for imported active pharmaceutical ingredients and formulation equipment. Segments such as tablets, capsules, and injectable dosage forms are particularly affected, with North American and Asia-Pacific regions facing notable import duties. This has led to higher production costs and potential delays in drug availability. On the positive side, tariffs encourage local manufacturing, innovation in cost-effective drug development, and diversification of supply chains.

The tardive dyskinesia therapeutics market research report is one of a series of new reports from The Business Research Company that provides tardive dyskinesia therapeutics market statistics, including tardive dyskinesia therapeutics industry global market size, regional shares, competitors with a tardive dyskinesia therapeutics market share, detailed tardive dyskinesia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the tardive dyskinesia therapeutics industry. This tardive dyskinesia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tardive dyskinesia therapeutics market size has grown strongly in recent years. It will grow from $3.12 billion in 2025 to $3.35 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to limited treatment options for tardive dyskinesia, reliance on conventional antipsychotic management, low patient awareness, growing prevalence of antipsychotic use, restricted specialty treatment centers.

The tardive dyskinesia therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.39 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to development of novel therapeutics for tardive dyskinesia, increased r&d investment in neurological disorders, rising preference for homecare settings, expansion of specialty treatment centers, enhanced patient monitoring and digital therapeutics. Major trends in the forecast period include rising adoption of deutetrabenazine and valbenazine, increased focus on personalized neurological therapy, expansion of homecare and remote treatment options, growing awareness about drug-induced tardive dyskinesia, emphasis on safety and compliance in long-term treatment.

The rising prevalence of mental health disorders is anticipated to drive the growth of the tardive dyskinesia therapeutics market in the coming years. Mental health disorders are conditions that impact an individual's thoughts, emotions, behavior, or overall functioning, often leading to significant distress or challenges in everyday life. The increase in mental health disorders is largely attributed to growing social isolation, as greater reliance on digital communication and fast-paced lifestyles has reduced meaningful face-to-face interactions, resulting in heightened feelings of loneliness and emotional stress. Tardive dyskinesia therapeutics assist patients with mental disorders by managing involuntary movement symptoms associated with long-term antipsychotic use, thereby supporting treatment adherence and improving overall quality of life. For instance, in 2024, according to the National Alliance on Mental Illness, a US-based organization, psychosis spectrum and mood disorders accounted for nearly 600,000 hospitalizations annually among individuals in the U.S. aged 18 to 44. Therefore, the increasing prevalence of mental health disorders is driving the growth of the tardive dyskinesia therapeutics market.

Major companies operating in the tardive dyskinesia therapeutics market are concentrating on developing advanced products, such as once-daily treatment options, to ensure more consistent drug levels in the body. Once-daily treatment options are therapies designed to be administered a single time each day, simplifying dosing regimens and enhancing patient compliance. For example, in May 2024, Teva Pharmaceutical Industries Limited, an Israel-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved AUSTEDO XR tablets for the treatment of adults with tardive dyskinesia (TD) and Huntington's disease (HD) chorea. The approval of AUSTEDO XR provides patients with proven efficacy in controlling involuntary movements along with the convenience of a once-daily, single-tablet regimen. This formulation delivers clinically effective doses validated through pivotal clinical trials and is available in four tablet strengths: 30 mg, 36 mg, 42 mg, and 48 mg.

In February 2024, Teva Pharmaceutical Industries Limited partnered with Jiangsu Nhwa Pharmaceutical Co. Ltd. to promote and distribute Teva's AUSTEDO. Through this collaboration, the companies aim to expand patient access to AUSTEDO by leveraging Nhwa's strong presence in China's neuropsychiatric healthcare market. AUSTEDO is recognized as the first vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. FDA for the treatment of tardive dyskinesia and chorea associated with Huntington's disease in adults. Jiangsu Nhwa Pharmaceutical Co. Ltd. is a China-based pharmaceutical company.

Major companies operating in the tardive dyskinesia therapeutics market are Neurocrine Biosciences Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Lundbeck A/S, Mitsubishi Tanabe Pharma Corporation, AbbVie Inc., Pfizer Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Zydus Lifesciences Ltd., Lupin Limited, Amneal Pharmaceuticals Inc., Lannett Company Inc., Alembic Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals PLC, Accord Healthcare Ltd., Cipla Ltd., Glenmark Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Indivior PLC, Viatris Inc., Alkem Laboratories Ltd., Intas Pharmaceuticals Ltd., Som Biotech Ltd., Addex Therapeutics Ltd., Luye Pharma Group Ltd., Apotex Inc., Sandoz Group AG, Torrent Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Taro Pharmaceutical Industries Ltd., Cadila Pharmaceuticals Ltd.

North America was the largest region in the tardive dyskinesia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tardive dyskinesia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the tardive dyskinesia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tardive dyskinesia therapeutics market consists of revenues earned by entities by providing services such as drug discovery, clinical trial management, formulation services, and pharmacovigilance. The market value includes the value of related goods sold by the service provider or included within the service offering. The tardive dyskinesia therapeutics market also includes sales of adjunctive medications, patient monitoring devices, drug delivery systems, and screening tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tardive Dyskinesia Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses tardive dyskinesia therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tardive dyskinesia therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tardive dyskinesia therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug: Deutetrabenazine; Valbenazine; Other Drugs
• 2) By Product Type: Solid Dosage Forms; Tablets; Capsules; Liquid Dosage Form
• 3) By Application: Antipsychotic-Induced Tardive Dyskinesia; Other Drug-Induced Tardive Dyskinesia; Idiopathic Tardive Dyskinesia
• 4) By End-User: Hospitals; Clinics; Specialty Treatment Centers; Homecare Settings
• Subsegments:
• 1) By Deutetrabenazine: Dosage Forms; Line Of Therapy; Distribution Channel
• 2) By Valbenazine: Dosage Forms; Patient Age Group; Distribution Channel
• 3) By Other Drugs: Drug Class Or Type; Dosage Forms; Treatment Duration
• Companies Mentioned: Neurocrine Biosciences Inc.; Teva Pharmaceutical Industries Ltd.; Otsuka Pharmaceutical Co. Ltd.; Lundbeck A/S; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; Pfizer Inc.; Novartis AG; Sun Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Zydus Lifesciences Ltd.; Lupin Limited; Amneal Pharmaceuticals Inc.; Lannett Company Inc.; Alembic Pharmaceuticals Ltd.; Aurobindo Pharma Ltd.; Hikma Pharmaceuticals PLC; Accord Healthcare Ltd.; Cipla Ltd.; Glenmark Pharmaceuticals Ltd.; Sunovion Pharmaceuticals Inc.; Indivior PLC; Viatris Inc.; Alkem Laboratories Ltd.; Intas Pharmaceuticals Ltd.; Som Biotech Ltd.; Addex Therapeutics Ltd.; Luye Pharma Group Ltd.; Apotex Inc.; Sandoz Group AG; Torrent Pharmaceuticals Ltd.; Jubilant Pharmova Ltd.; Taro Pharmaceutical Industries Ltd.; Cadila Pharmaceuticals Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.